Dr. Alison Moskowitz, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Area of expertise
Lymphoma
Alison Moskowitz, MD has run 5 trials for Lymphoma. Some of their research focus areas include:
Hodgkin's Disease
Alison Moskowitz, MD has run 3 trials for Hodgkin's Disease. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Westchester
Clinical Trials Alison Moskowitz, MD is currently running
Ruxolitinib + Duvelisib
for Lymphoma
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).
Recruiting
1 award
Phase 1
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting
1 award
Phase 2
27 criteria
More about Alison Moskowitz, MD
Clinical Trial Related
9 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Alison Moskowitz, MD has experience with
- Pembrolizumab
- Ruxolitinib
- Duvelisib
- Gemcitabine
- Doxorubicin
- Entinostat
Breakdown of trials Alison Moskowitz, MD has run
Lymphoma
Hodgkin's Disease
Hodgkin's Lymphoma
T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alison Moskowitz, MD specialize in?
Alison Moskowitz, MD focuses on Lymphoma and Hodgkin's Disease. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage III.
Is Alison Moskowitz, MD currently recruiting for clinical trials?
Yes, Alison Moskowitz, MD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alison Moskowitz, MD has studied deeply?
Yes, Alison Moskowitz, MD has studied treatments such as Pembrolizumab, Ruxolitinib, Duvelisib.
What is the best way to schedule an appointment with Alison Moskowitz, MD?
Apply for one of the trials that Alison Moskowitz, MD is conducting.
What is the office address of Alison Moskowitz, MD?
The office of Alison Moskowitz, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.